Gilead Announces Response Data from Phase 2 Study of Idelalisib for ... Fort Mills Times Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with ... New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia |
